Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126528221 | 12652822 | 1 | I | 20160719 | 20160804 | 20160815 | 20160815 | EXP | US-NOVOPROD-504785 | NOVO NORDISK | 73.00 | YR | E | F | Y | 48.98000 | KG | 20160815 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126528221 | 12652822 | 1 | PS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 0.6 MG, QD | .5 | MG | Y | ES6R934 | 22341 | .6 | MG | SOLUTION FOR INJECTION | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126528221 | 12652822 | 1 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126528221 | 12652822 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126528221 | 12652822 | Constipation | |
| 126528221 | 12652822 | Cystitis | |
| 126528221 | 12652822 | Dehydration | |
| 126528221 | 12652822 | Kidney infection | |
| 126528221 | 12652822 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126528221 | 12652822 | 1 | 20160719 | 20160723 | 0 |